VRX Stock is down on a downgrade and PT $7 today. $BHC, Bausch Health Companies Inc. / H1 VRX stock needs a catalyst. Vyzulta's approval is what Valeant needs but this event depends on the FDA. Management's re-iteration of its guidance may give the stock a boost. Otherwise, wait for Q3 results.Related: ENDP stock is rebounding. Teva (TEVA) has yet to bottom.Agree: Positive catalysts await for VRX stockDisagree: more downside.Login via StockTwits to vote now.